The anti-vascular endothelial growth factor (anti-VEGF) drug Bevacizumab (Avastin Genentech Inc. (Roche Group), San Francisco, California, USA) has been in circulation for several years within the ophthalmic community. Numerous studies have reported clinical outcomes of Bevacizumab in the context of proliferative diabetic retinopathy (PDR)1–4 and neovascular glaucoma. These, including a comprehensive review5 and a meta-analysis,6 have all reported favourable clinical outcomes. Studies therefore confirm that Bevacizumab reduces the risk of haemorrhage, reduces the need for endodiathermy, facilitates surgery and reduces surgical time if administered days prior to vitrectomy surgery for PDR. Bevacizumab also reduces retinal neovascularisation and/or iris neovascularisation in patients with rubeotic glaucoma secondary to advanced PDR when used …